No. 23-235October Term 2023Decided Jun 13, 2024
FDA v. Alliance for Hippocratic Medicine
The Court unanimously held that the doctor and association plaintiffs lacked Article III standing to challenge the FDA's mifepristone actions.
Case status
- Current stage
- Decided
- Latest event
- Decision released Jun 13, 2024
- What it's about
The Court unanimously held that the doctor and association plaintiffs lacked Article III standing to challenge the FDA's mifepristone actions. Because standing was absent, the Court did not reach the merits of the FDA's regulatory decisions.
Question presented
1. Do respondents have Article III standing to challenge the Food and Drug Administration’s 2016 and 2021 actions with respect to mifepristone’s approved conditions of use? 2. Were the FDA’s 2016 and 2021 approvals of mifepristone arbitrary and capricious? 3. Did the district court properly grant preliminary relief?
- Case path
United States Court of Appeals for the Fifth Circuit / Decision released Jun 13, 2024
- Area
Constitutional Law
Related cases
Grounding
- Grounding
- Primary-source trail available.
- Note
- Plain-English explainer. Official filings and opinions remain authoritative.
- Checked
- Mar 30, 2026
- Method
- Methodology